Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1991 1
1994 1
1999 2
2002 2
2012 1
2013 1
2016 1
2019 1
2020 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Sequential radiofrequency ablation and surgical debulking for unresectable colorectal carcinoma: thermo-surgical ablation.
Ripley RT, Gajdos C, Reppert AE, Macdermott T, McCarter MD, Pearlman NW. Ripley RT, et al. J Surg Oncol. 2013 Feb;107(2):144-7. doi: 10.1002/jso.23211. Epub 2012 Aug 23. J Surg Oncol. 2013. PMID: 22927225
METHODS: We reviewed a prospective database of patients undergoing thermo-surgical ablation for unresectable colorectal carcinoma from 2003 to 2011. RESULTS: Sixteen patients were treated with unresectable, recurrent abdomino-pelvic colorectal carcinoma: 11 i …
METHODS: We reviewed a prospective database of patients undergoing thermo-surgical ablation for unresectable colorectal car …
Intratumoral Budding in Pretreatment Biopsies, among Tumor Microenvironmental Components, Can Predict Prognosis and Neoadjuvant Therapy Response in Colorectal Adenocarcinoma.
Yim K, Jang WM, Cho U, Sun S, Chong Y, Seo KJ. Yim K, et al. Medicina (Kaunas). 2022 Jul 12;58(7):926. doi: 10.3390/medicina58070926. Medicina (Kaunas). 2022. PMID: 35888645 Free PMC article.
Background and Objectives: The prediction of the prognosis and effect of neoadjuvant therapy is vital for patients with advanced or unresectable colorectal carcinoma (CRC). Materials and Methods: We investigated several tumor microenvironment factors, such as …
Background and Objectives: The prediction of the prognosis and effect of neoadjuvant therapy is vital for patients with advanced or unres …
Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy.
Alexander HR Jr, Libutti SK, Bartlett DL, Pingpank JF, Kranda K, Helsabeck C, Beresnev T. Alexander HR Jr, et al. Cancer. 2002 Aug 15;95(4):730-6. doi: 10.1002/cncr.10686. Cancer. 2002. PMID: 12209715 Free article.
In the current study, the authors present their results using vascular isolation and perfusion of the liver for individuals with progressive, unresectable liver metastases from colorectal carcinoma that were refractory to both previous systemic and regional chemotherapy. METHODS: …
In the current study, the authors present their results using vascular isolation and perfusion of the liver for individuals with progressive …
The significance of transarterial chemoembolization combined with systemic chemotherapy for patients with KRAS wild-type unresectable metachronous colorectal carcinoma with liver metastases.
Yu Q, Zhang L, Fan S, Huang L, Wang X, Xindun C. Yu Q, et al. J Cancer Res Ther. 2016 Dec;12(Supplement):C205-C211. doi: 10.4103/0973-1482.200603. J Cancer Res Ther. 2016. PMID: 28230018 Free article.
PURPOSE: The purpose of this study was to assess the survival benefits of transarterial chemoembolization (TACE) combined with systemic chemotherapy as the first-line treatment for metachronous unresectable colorectal carcinoma with liver metastases (CLMs) an …
PURPOSE: The purpose of this study was to assess the survival benefits of transarterial chemoembolization (TACE) combined with systemic chem …
Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody.
Kim JA, Bresler HS, Martin EW Jr, Aldrich W, Heffelfinger M, Triozzi PL. Kim JA, et al. Cancer. 1999 Jul 1;86(1):22-30. Cancer. 1999. PMID: 10391559 Clinical Trial.
METHODS: Tumor-reactive lymph nodes containing radiolabeled MoAb were localized and excised from 32 patients with metastatic, unresectable colorectal carcinoma at laparotomy. Lymph nodes were dissociated, and cells were cultured ex vivo for 10-14 days. ...
METHODS: Tumor-reactive lymph nodes containing radiolabeled MoAb were localized and excised from 32 patients with metastatic, unresectabl …
The usefulness of pharmacokinetic modulating chemotherapy (UFT plus 5FU) in the treatment of unresectable colorectal carcinomas.
Kusunoki M, Yanagi H, Noda M, Yamamura T. Kusunoki M, et al. Oncol Rep. 1999 May-Jun;6(3):547-52. doi: 10.3892/or.6.3.547. Oncol Rep. 1999. PMID: 10203589 Clinical Trial.
One of 56 patients who received PMC developed grade 4 toxicity. PMC significantly improved the prognosis of unresectable colorectal carcinoma which has a low survival rate. PMC also indicated tolerable compliance and cost effectiveness....
One of 56 patients who received PMC developed grade 4 toxicity. PMC significantly improved the prognosis of unresectable colorecta …
Echogenicity of liver metastases from colorectal carcinoma is an independent prognostic factor in patients treated with regional chemotherapy.
Gruenberger T, Zhao J, King J, Chung T, Clingan PR, Morris DL. Gruenberger T, et al. Cancer. 2002 Mar 15;94(6):1753-9. doi: 10.1002/cncr.10386. Cancer. 2002. PMID: 11920538 Free article.
The current analysis focuses on the influence of echogenicity on survival in patients treated with intraarterial chemotherapy for unresectable colorectal carcinoma liver metastases. METHODS: A retrospective analysis of prospectively collected data at the Depa …
The current analysis focuses on the influence of echogenicity on survival in patients treated with intraarterial chemotherapy for unresec …
A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma.
Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Margolin KA, Rayner AA, Sznol M, Parkinson DR, Paietta E, et al. Hawkins MJ, et al. J Immunother Emphasis Tumor Immunol. 1994 Jan;15(1):74-8. doi: 10.1097/00002371-199401000-00010. J Immunother Emphasis Tumor Immunol. 1994. PMID: 8110733 Clinical Trial.
Patients (n = 22) with metastatic or unresectable colorectal carcinoma were treated with interleukin (IL)-2 and lymphokine-activated killer (LAK) cells in a phase II study conducted by the IL-2/LAK Working Group (ILWG). ...
Patients (n = 22) with metastatic or unresectable colorectal carcinoma were treated with interleukin (IL)-2 and lymphok …
Treatment of patients with advanced colorectal cancer with cisplatin, 5-fluorouracil, and leucovorin.
Scheithauer W, Rosen H, Schiessel R, Schüller J, Karall M, Ernst F, Sebesta C, Kornek G, Hentschel E, Marczell A, et al. Scheithauer W, et al. Cancer. 1991 Mar 1;67(5):1294-8. doi: 10.1002/1097-0142(19910301)67:5<1294::aid-cncr2820670504>3.0.co;2-m. Cancer. 1991. PMID: 1991292 Clinical Trial.
Based on in vitro studies that have demonstrated synergy between 5-fluorouracil (5-FU), leucovorin (LV), and cisplatin (CDDP) against human colon cancer cell lines, a clinical trial was initiated to determine the effects of this combination in patients with advanced unresectab …
Based on in vitro studies that have demonstrated synergy between 5-fluorouracil (5-FU), leucovorin (LV), and cisplatin (CDDP) against human …
11 results